本研究的目的是评估在 83 名诊断为胶质母细胞瘤的患者中通过肿瘤组织中的免疫组织化学测定的斯钙素 2 (STC2) 表达的预后相关性，这些患者接受了最大程度的安全手术切除，随后接受了与辅助替莫唑胺同时进行的放疗。使用3级半定量系统对STC2表达水平进行分类：阴性表达（水平0-）、低表达（水平1）和高表达（水平2  和3）。根据 STC2 表达水平，患者被分为 2 个不同的组：阴性 STC2 (-/ ) 和阳性 STC2 ( / )。主要结局指标是 STC2 表达与无进展生存期 (PFS) 之间的关系，总生存期 (OS) 作为次要终点。 Kaplan-Meier 生存分析证实，与 STC2 低表达或阴性表达的患者相比，STC2 高表达患者的 OS（8 个月 vs 20 个月，P < .001）和 PFS（6 vs 18 个月，P <0.001）显着缩短。多变量分析显示，STC2 表达是 OS（风险比：0.4；95% 置信区间：0.2-0.8；P < .05）和 PFS（风险比：0.3；95% 置信区间：0.2-0.4）的独立预后因素; P < .05) 胶质母细胞瘤患者。此外，GBM中STC2表达升高与一些已确定的侵袭性临床病理特征相关，包括高龄（≥65岁）、低ECOG PS（≥2）和异柠檬酸脱氢酶突变阴性。这些发现强调，GBM 患者肿瘤组织内 STC2 表达升高可作为不良预后标志物，与进展风险升高和 OS 降低相关。针对 AKT-mTOR、ERK1-2 和丝裂原激活蛋白激酶途径的治疗干预措施以及免疫检查点抑制剂和血管内皮生长因子阻断，以及即将推出的针对 STC2 分子的抗体-药物偶联物，有可能扩大联合治疗策略的范围。作者版权所有 © 2024。由 Wolters Kluwer Health, Inc. 出版

The objective of this study was to assess the prognostic relevance of Stanniocalcin-2 (STC2) expression, as determined via immunohistochemistry in tumor tissue, in a cohort of 83 patients diagnosed with glioblastoma who underwent maximal safe surgical resection followed by radiotherapy concurrent with adjuvant temozolomide. STC2 expression levels were categorized using a 3-tiered semiquantitative system: negative expression (level 0-), low expression (level 1+), and high expression (levels 2 + and 3+). Patients were categorized into 2 distinct groups according to their STC2 expression levels: negative STC2 (-/+) and positive STC2 (++/+++). The primary outcome measure was the relationship between STC2 expression and progression-free survival (PFS), with overall survival (OS) serving as the secondary endpoint. Kaplan-Meier survival analysis confirmed that patients exhibiting high STC2 expression had significantly shorter OS (8 vs 20 months, P < .001) and PFS (6 vs 18 months, P < .001) than those with low or negative STC2 expression. Multivariate analysis revealed that STC2 expression was an independent prognostic factor for both OS (hazard ratio: 0.4; 95% confidence interval: 0.2-0.8; P < .05) and PFS (hazard ratio: 0.3; 95% confidence interval: 0.2-0.4; P < .05) in patients with glioblastoma. Furthermore, elevated STC2 expression in GBM was correlated with several established aggressive clinicopathological characteristics, including advanced age (≥65 years), low ECOG PS (≥2), and isocitrate dehydrogenase mutation negativity. These findings underscore that heightened STC2 expression within the tumor tissue of GBM patients functions as an adverse prognostic marker, correlating with an elevated risk of progression and reduced OS. Therapeutic interventions targeting the AKT-mTOR, ERK1-2, and mitogen-activated protein kinase pathways as well as immune checkpoint inhibitors and vascular endothelial growth factor blockade, as well as potential forthcoming antibody-drug conjugates targeting the STC2 molecule, have the potential to broaden the scope of combined treatment strategies.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.